CBIO Stock Overview
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Catalyst Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.28 |
| 52 Week High | US$2.09 |
| 52 Week Low | US$0.20 |
| Beta | 1.38 |
| 1 Month Change | -46.54% |
| 3 Month Change | -49.28% |
| 1 Year Change | -53.42% |
| 3 Year Change | -96.24% |
| 5 Year Change | -98.93% |
| Change since IPO | -99.79% |
Recent News & Updates
Recent updates
Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11
Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Shareholder Returns
| CBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.1% | -1.4% | 0.2% |
| 1Y | -53.4% | 1.2% | -13.6% |
Return vs Industry: CBIO underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: CBIO underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| CBIO volatility | |
|---|---|
| CBIO Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CBIO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: CBIO's weekly volatility has decreased from 37% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 45 | Nassim Usman | https://www.catalystbiosciences.com |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company’s protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD.
Catalyst Biosciences, Inc. Fundamentals Summary
| CBIO fundamental statistics | |
|---|---|
| Market Cap | US$10.65m |
| Earnings (TTM) | US$11.88m |
| Revenue (TTM) | US$3.23m |
0.9x
P/E Ratio3.3x
P/S RatioIs CBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBIO income statement (TTM) | |
|---|---|
| Revenue | US$3.23m |
| Cost of Revenue | US$27.14m |
| Gross Profit | -US$23.90m |
| Other Expenses | -US$35.79m |
| Earnings | US$11.88m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | -739.18% |
| Net Profit Margin | 367.44% |
| Debt/Equity Ratio | 0% |
How did CBIO perform over the long term?
See historical performance and comparison